Predictive value of early serum cytokine changes on long-term interferon beta-1a efficacy in multiple sclerosis.

Abstract

BACKGROUND:

In a previous study, we had evaluated short-term effects of interferon beta-1a (IFNB-1a) 44 μg s.c. three times per week treatment on serum levels of IFN-gamma (IFNG), IL-23, IL-17, IL-10, IL-9, IL-4 and TGF-beta (TGFB) and found a reduction only in IL-17 and IL-23 levels after 2 months of treatment.

METHODS:

Using the same multiple sclerosis (MS) cohort, we assessed the predictive value of early cytokine level changes (difference between 2nd month and baseline levels as measured by ELISA) on the efficacy of long-term IFNB-1a treatment.

RESULTS:

The alteration in IFNG levels of patients without any relapse was statistically lower than that of patients having one or more relapses (p = 0.019, Student's t-test). When patients with or without expanded disability severity scale (EDSS) progression were compared, none of the cytokine level changes showed a significant difference between groups. IL-17 and IL-23 level changes did not predict relapse and EDSS progression in IFNB-1a-treated MS patients.

CONCLUSION:

Our results show that the predictive power of early IFNG measurement on relapse occurrence may potentially extend a time span of several years.

• Authors: Belgin Petek-Balcı, Arzu Çoban, Erkingül Shugaiv, Recai Türkoğlu, Canan Ulusoy, Sema İçöz, Münevver Pehlivan, Erdem Tüzün, Gülşen Akman-Demir, Murat Kürtüncü, Mefküre Eraksoy
• Journal: The International journal of neuroscience (Int J Neurosci) Vol. 125 Issue 5 Pg. 352-6 (May 2015) ISSN: 1563-5279 [Electronic] England
• PMID: 25026220 (Publication Type: Journal Article)

Chemical References

• Adjuvants, Immunologic
• Cytokines
• Interferon beta-1a

Topics

• Adjuvants, Immunologic (therapeutic use)
• Adult
• Cohort Studies
• Cytokines (blood)
• Disability Evaluation
• Enzyme-Linked Immunosorbent Assay
• Female
• Humans
• Interferon beta-1a (therapeutic use)
• Logistic Models
• Male
• Multiple Sclerosis, Relapsing-Remitting (blood, drug therapy)
• Predictive Value of Tests
• Time Factors